Skip to main content
Premium Trial:

Request an Annual Quote

Precision Cancer Diagnosis Firm Imagene AI Raises $21.5M

NEW YORK — Israeli precision oncology diagnosis startup Imagene AI said on Monday that it has raised $21.5 million in private financing.

The funding includes $3 million from a seed financing round led by Blumberg Capital and $18.5 million from a Series A round led by individual investors Larry Ellison, David Agus, and Eyal Gura.

Imagene AI was founded in 2020 to a develop a technology that uses artificial intelligence to detect molecular cancer biomarkers from digital biopsy images. The approach enables the classification of genomic, proteomic, and spatial patterns that relate to cancer recurrence and treatment resistance, supporting patient stratification in clinical trials and drug target discovery, according to the company.

"Though cancer is a complex disease we might never fully understand, AI is bringing us closer to considering all relevant parameters that affect it, allowing a move towards theragnostics: a personal treatment strategy that combines therapeutics with diagnostics," Agus said in a statement. "Imagene's technology can unlock precise and crucial information in real time, changing the way cancer is diagnosed and treated."